18524141. METHOD OF IDENTIFYING FEATURE OF TEST BODY AND MICRORNA CANCER MARKER simplified abstract (KABUSHIKI KAISHA TOSHIBA)
Contents
METHOD OF IDENTIFYING FEATURE OF TEST BODY AND MICRORNA CANCER MARKER
Organization Name
Inventor(s)
Mitsuko Ishihara of Setagaya (JP)
METHOD OF IDENTIFYING FEATURE OF TEST BODY AND MICRORNA CANCER MARKER - A simplified explanation of the abstract
This abstract first appeared for US patent application 18524141 titled 'METHOD OF IDENTIFYING FEATURE OF TEST BODY AND MICRORNA CANCER MARKER
The abstract describes a method for identifying features of a test body by measuring mutation-specific concentrations of miRNA, correcting these values, and using the change in concentration to determine if the test body is cancerous or non-cancerous.
- Measurement of mutation-specific concentrations of miRNA in the test body
- Correction of these concentrations
- Determination of cancerous or non-cancerous nature based on the change in concentration
Potential Applications: - Early detection of cancer - Personalized medicine based on miRNA profiles - Monitoring cancer progression and treatment effectiveness
Problems Solved: - Accurate identification of cancerous cells - Non-invasive method for cancer detection - Personalized treatment based on molecular markers
Benefits: - Early diagnosis leading to better treatment outcomes - Reduced need for invasive procedures - Tailored treatment plans for individual patients
Commercial Applications: Title: "Innovative Cancer Detection Method for Personalized Medicine" This technology could be used in medical diagnostics companies, cancer research institutions, and healthcare facilities to improve cancer detection and treatment strategies.
Questions about the technology: 1. How does this method compare to traditional cancer diagnostic techniques? 2. What are the potential limitations of using miRNA concentrations for cancer detection?
Frequently Updated Research: Researchers are continually exploring new miRNA biomarkers and refining methods for cancer detection and treatment. Stay updated on the latest studies in this field to enhance the effectiveness of this technology.
Original Abstract Submitted
According to one embodiment, method of identifying feature of test body is provided. The method includes measuring a mutation-specific concentration of at least one miRNA contained in the test body, correcting a value of the mutation-specific concentration, and determining whether the test body is a cancer or a non-cancer one using an increase or decrease in the corrected mutation-specific concentration as index.
